163 related articles for article (PubMed ID: 29127353)
1. Clinicopathological and prognostic significance of PKM2 protein expression in cirrhotic hepatocellular carcinoma and non-cirrhotic hepatocellular carcinoma.
Liu Y; Wu H; Mei Y; Ding X; Yang X; Li C; Deng M; Gong J
Sci Rep; 2017 Nov; 7(1):15294. PubMed ID: 29127353
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Pyruvate Kinase M2 in Tumor Tissues Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Zhao R; Li L; Yang J; Niu Q; Wang H; Qin X; Zhu N; Shi A
Pathol Oncol Res; 2020 Apr; 26(2):853-860. PubMed ID: 30852741
[TBL] [Abstract][Full Text] [Related]
3. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma.
Hu W; Lu SX; Li M; Zhang C; Liu LL; Fu J; Jin JT; Luo RZ; Zhang CZ; Yun JP
Oncotarget; 2015 Mar; 6(9):6570-83. PubMed ID: 25788265
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of pyruvate kinase M2 isoform inhibits cell motility in hepatocellular carcinoma cells.
Chen YL; Song JJ; Chen XC; Xu W; Zhi Q; Liu YP; Xu HZ; Pan JS; Ren JL; Guleng B
World J Gastroenterol; 2015 Aug; 21(30):9093-102. PubMed ID: 26290635
[TBL] [Abstract][Full Text] [Related]
5. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma.
Xu Q; Tu J; Dou C; Zhang J; Yang L; Liu X; Lei K; Liu Z; Wang Y; Li L; Bao H; Wang J; Tu K
Mol Cancer; 2017 Dec; 16(1):178. PubMed ID: 29262861
[TBL] [Abstract][Full Text] [Related]
6. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.
Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH
Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599
[TBL] [Abstract][Full Text] [Related]
7. Nuclear PKM2 expression, an independent risk factor for ER after curative resection of hepatocellular carcinoma.
Fan F; Wu H; Liu Z; Hou X; Chen W; Wang A; Lu Y
Biomed Pharmacother; 2016 Dec; 84():1858-1864. PubMed ID: 27894667
[TBL] [Abstract][Full Text] [Related]
8. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
[TBL] [Abstract][Full Text] [Related]
9. Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma.
Chen Z; Lu X; Wang Z; Jin G; Wang Q; Chen D; Chen T; Li J; Fan J; Cong W; Gao Q; He X
Oncotarget; 2015 Feb; 6(4):2538-48. PubMed ID: 25576919
[TBL] [Abstract][Full Text] [Related]
10. COX-2 induces apoptosis-resistance in hepatocellular carcinoma cells via the HIF-1α/PKM2 pathway.
Wang Q; Lu D; Fan L; Li Y; Liu Y; Yu H; Wang H; Liu J; Sun G
Int J Mol Med; 2019 Jan; 43(1):475-488. PubMed ID: 30365092
[TBL] [Abstract][Full Text] [Related]
11. Expression of Kindlin-1 in human hepatocellular carcinoma and its prognostic significance.
Ma HX; Shu QH; Pan JJ; Liu D; Xu GL; Li JS; Ma JL; Jia WD; Yv JH; Ge YS
Tumour Biol; 2015 Jun; 36(6):4235-41. PubMed ID: 25592379
[TBL] [Abstract][Full Text] [Related]
12. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis.
Wong CC; Au SL; Tse AP; Xu IM; Lai RK; Chiu DK; Wei LL; Fan DN; Tsang FH; Lo RC; Wong CM; Ng IO
PLoS One; 2014; 9(12):e115036. PubMed ID: 25541689
[TBL] [Abstract][Full Text] [Related]
13. Effects of PKM2 on global metabolic changes and prognosis in hepatocellular carcinoma: from gene expression to drug discovery.
Lv WW; Liu D; Liu XC; Feng TN; Li L; Qian BY; Li WX
BMC Cancer; 2018 Nov; 18(1):1150. PubMed ID: 30463528
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.
Chen D; Chen Y; Yan Y; Pan J; Xing W; Li Q; Zeng W
BMC Cancer; 2017 Aug; 17(1):553. PubMed ID: 28821282
[TBL] [Abstract][Full Text] [Related]
15. High NEK2 Expression Is a Predictor of Tumor Recurrence in Hepatocellular Carcinoma Patients After Hepatectomy.
Wubetu GY; Morine Y; Teraoku H; Yoshikawa M; Ishikawa D; Yamada S; Ikemoto T; Saito YU; Imura S; Shimada M
Anticancer Res; 2016 Feb; 36(2):757-62. PubMed ID: 26851035
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues.
Deli G; Jin CH; Mu R; Yang S; Liang Y; Chen D; Makuuchi M
World J Gastroenterol; 2005 Feb; 11(7):960-3. PubMed ID: 15742396
[TBL] [Abstract][Full Text] [Related]
17. Differences between hepatocellular carcinoma and hepatitis B virus infection in patients with and without cirrhosis.
Kim JM; Kwon CH; Joh JW; Park JB; Lee JH; Kim SJ; Paik SW; Park CK; Yoo BC
Ann Surg Oncol; 2014 Feb; 21(2):458-65. PubMed ID: 24132624
[TBL] [Abstract][Full Text] [Related]
18. PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment.
Li TE; Wang S; Shen XT; Zhang Z; Chen M; Wang H; Zhu Y; Xu D; Hu BY; Wei R; Zheng Y; Dong QZ; Qin LX
Front Immunol; 2020; 11():589997. PubMed ID: 33193421
[TBL] [Abstract][Full Text] [Related]
19. Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma.
Dayton TL; Gocheva V; Miller KM; Israelsen WJ; Bhutkar A; Clish CB; Davidson SM; Luengo A; Bronson RT; Jacks T; Vander Heiden MG
Genes Dev; 2016 May; 30(9):1020-33. PubMed ID: 27125672
[TBL] [Abstract][Full Text] [Related]
20. [Influence of cirrhosis on long-term outcomes after liver resection in patients with a single small hepatocellular carcinoma].
Liang BY; Huang ZY; Liu YA; Hou P; Ji GB; Chen XP
Zhonghua Wai Ke Za Zhi; 2012 Oct; 50(10):865-9. PubMed ID: 23302452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
